Pi-Hui Liang

CEO
ImmunAdd, Inc.

Dr. Pi-Hui Liang joined ImmunAdd Inc. as the CEO in Oct. 2023, bringing over 30 years of experience in drug discovery and pharmaceuticals to enhance product development and progress at ImmunAdd.
Prior to join ImmunAdd, Dr. Liang is a professor at the School of Pharmacy, National Taiwan University. Her team focused on the development of immune-modifying small molecules, drug targeting therapy, and anticancer drug development. She has authored over 60 academic papers in several excellent journals, such as the Journal of Medicinal Chemistry, Proceedings of the National Academy of Sciences of the United States of America, Journal of the American Chemical Society, and most of as the corresponding authors. Her innovation research also granted more than 40 patents, and most of them were tech-transferred to pharma, including ImmunAdd. She has been honored with numerous National awards such as the Outstanding Research Award from the National Science Council, the Future Tech Award, the National Innovation Award, the Wu Ho-Su TBF Medical Award, etc. 
Dr. Liang obtained her Ph.D. from the School of Pharmacy at National Taiwan University, completed postdoctoral research at the Academia Sinica and the Scripps Research Institute in the United States, mentored by the pioneering expert in glycol-science, Academician Dr. Chi-Huey Wong.


 

Speech title & Synopsis

Startup of the Year

ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in the pharmaceutical and industrial sectors. ImmunAdd is dedicated to enhancing human health and well-being. ImmunAdd is a biotech pharmaceutical research and development company focusing on drug design and formulation development. 
Our first product, IA-05, is a truncated QS-21 analogue with improved tolerability, stability, and long-term immune responses in combination with various antigens. IA-05 is expected to lead novel utilities in the development of immunotherapies and therapeutic vaccines. Furthermore, IA-05 could be formulated in various types of formulations and could be combined with various types of adjuvants for broader usage. 
Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials. With our specialized knowledge in drug development, we aim to address the urgent needs in drug therapy and contribute to human health. Our pipeline covers vaccine adjuvant development, new formulation development, and novel drug conjugation strategies applied in vaccines, cancer, and immunotherapies.